Nomura Holdings
GALT icon

Nomura Holdings’s Galectin Therapeutics GALT Stock Holding History

Nomura Holdings’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-16,000
Closed -$67K – 1854
2015
Q1 		$67K Buy
+16,000
New +$57.2K ﹤0.01% 1634

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nomura Holdings's GALT Position: Q2 2015 in Review

Nomura Holdings sold out of Galectin Therapeutics (GALT) in Q2 2015, closing a stake of 16,000 shares — an estimated $67K sold.

Nomura Holdings first reported a position in GALT in Q1 2015 and held it in 1 quarter. The position peaked at $67K in Q1 2015. 58 funds tracked by Wall St. Rank hold GALT as of Q2 2015.

  • Nomura Holdings reported no remaining Galectin Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Nomura Holdings sold 16,000 Galectin Therapeutics shares in Q2 2015, an estimated $67K.
  • Nomura Holdings first reported a position in Galectin Therapeutics in Q1 2015 and held it in 1 quarter.
  • Nomura Holdings's Galectin Therapeutics position peaked at $67K in Q1 2015.
  • 58 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2015.

Based on Nomura Holdings's 13F filing for Q2 2015, filed 14 Aug 2015.